【摘要】 目的探讨急性脑卒中后及东菱迪芙治疗急性脑梗塞血浆MMP-9变化的临床意义。方法90例病例中脑出血为30例,脑梗塞60例;将脑梗塞组随机分为常规治疗组30例,东菱迪芙治疗组30例,采用ELISH方法监测各组入院时,治疗5d末的血浆MMP-9含量。结果(1)急性脑梗塞患者MMP-9在发病24h内迅速上升,发病5d末仍维持在较高水平,且与病变程度呈正相关。(2)脑出血患者5d内MMP-9含量明显高于脑梗塞组,与脑水肿体积大小呈正相关。(3)东菱迪芙治疗组和常规治疗组发病5d末的MMP-9含量无显著性差异(P>0.05)。结论MMP-9含量在脑梗塞的早期即开始升高,其水平与病情程度密切相关;东菱迪芙治疗急性脑梗塞不会增加颅内出血的危险;血浆MMP-9水平可反映脑出血患者血肿周围水肿的严重程度。动态测定MMP-9可以预测在脑梗塞治疗过程中并发出血的风险。更多还原

【Abstract】 Objective To investigate the changes of MMP-9 in acute stroke patients and the clinical significance of MMP-9 in patients with acute cerebral infarction treated with Batroxobin injection (DF-521). Methods This study enrolled 90 patients with acute stroke including 30 patients with cerebral hemorrhage and 60 patients with acute cerebral infarction. Patients with acute cerebral infarction were randomized into two groups: tradition-treated control group and Batroxobin-treated group with 30 patients in each group. MMP-9 content on admission and 5 days after treatment was detected with ELISA method. Results 1) MMP-9 level in patients with acute cerebral infarction increased rapidly within 24 hours of onset,and maintained high level even 5 days after onset. MMP-9 was positive correlation with pathological extent. 2) MMP-9 level of patients with cerebral hemorrhage was higher than that of patients with acute cerebral infarction within 5 days of onset. MMP-9 was positive correlation with cerebral edema volume. 3) There was no difference between Batroxobin-treated group and control group in MMP-9 level after 5 days. Conclusion MMP-9 content increases in early phase of cerebral infarction and is associated with pathological changes. The use of Batroxobin injection in the treatment of acute cerebral infarction will not increase the risk of intracranial hemorrhage. MMP-9 level can reflect the severity of edema around the hematoma in patients with cerebral hemorrhage. Dynamic detection of MMP-9 can predict the risk of hemorrhage during treatment of cerebral infarction.更多还原